Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bifidobacterium Tetravaccine Tablets with dual therapy for Helicobacter pylori infection
ChiCTR2200060023Phase 4Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Dec 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Bifidobacterium tetravaccine in Helicobacter pylori infection (2 arms), sponsored by Nanjing First Hospital. Primary endpoints: H. pylori eradication rate and Adverse reaction assessment. Started Dec 2021; status: recruiting.
02
Drugs
Bifidobacterium tetravaccine
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200060023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060023.